JAKARTA, HARIANHALUAN.COM – On Monday (19/10), the World Health Organization (WHO) released a document regarding the update of the COVID-19 vaccine candidate being developed by a number of countries. A total of 44 vaccine candidates have entered the clinical trial stage and 10 of them have entered clinical trials phase 3 or the final phase.
“The inclusion of a specific product or entity in this landscape document does not constitute, and should not be construed or construed as, any approval or endorsement by WHO of that product or entity (or any of its businesses or activities),” WHO wrote on its official website as viewed detikcom, Saturday (24/10/2020).
Vaccines usually require years of research and testing before they reach the clinical trial stage. But scientists are racing against time to come up with a safe and effective COVID-19 vaccine.
Phase 3 clinical trials are conducted to determine whether a vaccine protects against the coronavirus. Stage 3 clinical trials are large enough to reveal evidence of relatively rare side effects that may have been missed in previous studies.
The following is a list of COVID-19 vaccine candidates that have entered phase 3 clinical trials:
1. Inactivated vaccine developed by Sinovac
2. Inactivated vaccine developed by Wuhan Institute of Biological Products / Sinopharm
3. Inactivated vaccine developed by Beijing Institute of Biological Products / Sinopharm
4. ChAdOx1-S vaccine developed by the University of Oxford / AstraZeneca
5. Ad5-nCoV vaccine developed by CanSino Biological Inc./Beijing Institute of Biotechnology
6. Vaccine (rAd26-S + rAd5-S) developed by the Gamaleya Research Institute
7. Ad26COVS1 vaccine developed by Janssen Pharmaceutical Companies
8. The Protein Subunit Vaccine developed by Novavax
9. LNP-encapsulated mRNA vaccine developed by Moderna / NIAID
10. Vaksin 3 LNP-mRNAs BioNTech/Fosun Pharma/Pfizer
–
